Erbitux and Infectious peritonitis - a phase IV clinical study of FDA data

Summary:

Infectious peritonitis is reported as a side effect among people who take Erbitux (cetuximab), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Cisplatin, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Infectious peritonitis when taking Erbitux. It is created by eHealthMe based on reports of 19,227 people who have side effects when taking Erbitux from the FDA, and is updated regularly.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

What is Infectious peritonitis?

Infectious peritonitis (inflammation of the peritoneum, typically caused by bacterial infection) is found to be associated with 135 drugs and 357 conditions by eHealthMe. Check the latest studies of Infectious peritonitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

19,227 people reported to have side effects when taking Erbitux.
Among them, 11 people (0.06%) have Infectious peritonitis.

Could Erbitux cause Infectious peritonitis?

Among these 11 people:

How long have people been on Erbitux when they have Infectious peritonitis? *

What is the gender of people who have Infectious peritonitis when taking Erbitux? *

female: 9.09 %
male: 90.91 %

What is the age of people who have Infectious peritonitis when taking Erbitux? *

What are other drugs people take besides Erbitux? *

What are other side effects people have besides Infectious peritonitis? *

Diverticular Perforation (serious gastrointestinal condition in which the intestine's walls are perforated): 10 people, 90.91%
Large Intestine Perforation (hole in large intestine): 1 person, 9.09%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 1 person, 9.09%
Disease Progression: 1 person, 9.09%
Dermatitis Acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis): 1 person, 9.09%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 10 people, 90.91%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Erbitux and have Infectious peritonitis?

- Check whether Infectious peritonitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erbitux:

Erbitux (19,276 reports)

Browse all side effects of Erbitux:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infectious peritonitis:

Infectious peritonitis (135 drugs)

Browse all the conditions that are associated with Infectious peritonitis:

Infectious peritonitis (357 conditions)

Related publications that referenced our studies

Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .
Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cetuximab (the active ingredients of Erbitux) and Erbitux (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.